INMB (INmune Bio) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 08, 2026)


INMB INmune Bio Inc INMB
53 GF Score
Price $1.76
GF Value $1.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is INmune Bio 5-Year Yield-on-Cost %?

INmune Bio INMB +4.50% 53 5-Year Yield-on-Cost % is 0.00 as of Jul. 08, 2026. GuruFocus rates INMB with a GF Score™ of 53/100 and a GF Value™ of $1.82 (Fairly Valued). The stock has 5 warning signs investors should review. Among 152 Biotechnology companies, INmune Bio ranks worse than 657894.08% on this metric.

INmune Bio's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for INmune Bio's 5-Year Yield-on-Cost % or its related term are showing as below:



INMB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.665
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

INmune Bio  (NAS:INMB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


INmune Bio 5-Year Yield-on-Cost % Related Terms


INMB vs GRCE, NTRB, ABVC: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, INmune Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where INmune Bio's 5-Year Yield-on-Cost % falls into.


INMB
53GF Score
INmune Bio Inc INMB
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

INmune Bio 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of INmune Bio is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
INmune Bio (INMB) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #999999 out of 152 companies in the Biotechnology industry.
Is INmune Bio's 5-Year Yield-on-Cost % too high?
INmune Bio's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, INmune Bio ranks #999999 out of 152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, INmune Bio has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's 5-Year Yield-on-Cost % compare to GRCE and NTRB?
According to the Biotechnology industry distribution chart, INmune Bio ranks #999999 out of 152 companies for 5-Year Yield-on-Cost %. This places INmune Bio in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.67, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on INmune Bio and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Fairly Valued. The stock's GF Value™ is $1.82, compared to a current price of $1.76 — trading 3.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. INmune Bio's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For INmune Bio (INMB), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.76 is trading 3.6% below its estimated GF Value™ of $1.82. GuruFocus considers INmune Bio to be Fairly Valued.

Key valuation signals for INMB:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $1.82 vs. price of $1.76 (3.6% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
53GF Score

Get the complete analysis for INMB

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price
$1.82
GF Value